Plenty of marijuana law reform legislation was introduced in state legislatures across the country this week! We have news out of Georgia, Kansas, Maryland, New Hampshire, Utah and Washington. Plus some news from abroad! Keep reading below to get the latest news in marijuana law reform from this week.
Chile: A medical marijuana farm in the country was officially “inaugurated” this week, signifying a growing approval of medical marijuana use in the region. The farm is the largest medical marijuana plantation in Latin America and will provide medicine to about 4,000 patients in the country.
Israel: The Knesset Labor, Social Affairs and Health Committee held a joint session with the Anti-Drug and Alcohol Committee to discuss reform of the country’s medical marijuana regulations. Currently only a small number of doctors can prescribe the medicine and there is a shortage of supply so officials are looking to expand physician privileges to prescribe cannabis.
“People are dying and suffering [from lack of the drug],” they said. “We have heard grandiose promises, but so far there are no answers. There is plenty of bureaucracy that doesn’t know how to deal with individual cases.
Mexico: After a series of public debates and bipartisan support, a bill to allow the importation of medical marijuana products is expected to pass by May.
“The bill, proposed by Institutional Revolutionary Party Senator Cristina Diaz, aims to change Mexican laws to allow the import of medical marijuana products to help the roughly 5,000 medical patients currently without access to such drugs.”
Georgia: A newly introduced Senate Resolution seeks to place a constitutional amendment on the November 2016 ballot to regulate adult marijuana use.
SR6 would allow voters to decide if they wish to regulate the commercial cultivation, processing, and retail of marijuana to adults over the age of 21. You can read the full text of this proposal here. To contact your lawmakers and urge their support for the measure, click here.
Kansas: Senate lawmakers are considering legislation, HB 2049, to amend various penalties and regulations specific to marijuana possession and use.
House Bill 2049 seeks to a) establish a statewide research program to oversee the production of industrial hemp, b) authorize the limited use of cannabidiol for therapeutic purposes, and c) reduce criminal penalties for first-time marijuana possession offenses from a Class A misdemeanor (punishable by up to one year incarceration and a $2,500 fine) to a Class B misdemeanor (punishable by no more than six months in jail and a $1,000 fine).
Click here to learn more and urge your lawmakers to support this legislation.
Maryland: January 21, members of the Maryland House and Senate voted to override a 2015 veto and to decriminalize the possession of marijuana paraphernalia.
Senate Bill 517 amends existing criminal penalties regarding the possession of marijuana-related paraphernalia from a misdemeanor, punishable by possible jail time, to a civil violation. However, amended language also includes a provision establishing a civil fine of up to $500 for offenses involving the use of marijuana in public. NORML and our affiliates will be working in the future to amend this penalty.
On January 27th, the House Criminal Justice and Public Safety Committee will be voting on the three separate bills that would legalize various amounts of marijuana.
For more information or to urge your lawmakers to support legalization in New Hampshire, click here.
House bill 1631, legislation to decriminalize the possession of small amounts of marijuana, is also pending in the House of Representatives.
Utah: SB 73, the Medical Cannabis Act, sponsored by Sen. Mark Madsen, was introduced this week and seeks to amend state law to permit for the state-licensed cultivation of cannabis, including strains with higher THC content, for the manufacturing of medicinal products and/or herbal preparations.
Under a 2014 law, qualifying patients are permitted to possess cannabis extracts that contain more than 15 percent CBD and no more than 0.3 percent THC. However, the law provides no legal supply source for these products and, as a result, it has largely failed to meet the needs of patients.
Competing legislation seeks to only permit the use of CBD in pill or oil form and prohibits any form of THC.
Click here to contact your lawmakers and urge them to support SB 73!
Washington: Newly introduced legislation, HB 2629, The Adult Home Grow & Criminal Reduction Bill would permit adults to grow a limited number of marijuana plants for personal use.
Click here to urge your lawmakers in Washington to support these measures.
Additional information for these and other pending legislative measures may be found at our #TakeAction Center!
** A note to first time readers: NORML can not introduce legislation in your state. Nor can any other non-profit advocacy organization. Only your state representatives, or in some cases an individual constituent (by way of their representative; this is known as introducing legislation ‘by request’) can do so. NORML can — and does — work closely with like-minded politicians and citizens to reform marijuana laws, and lobbies on behalf of these efforts. But ultimately the most effective way — and the only way — to successfully achieve statewide marijuana law reform is for local stakeholders and citizens to become involved in the political process and to make the changes they want to see. Get active; get NORML!
The administration of liquid cannabis extracts containing THC is associated with the mitigation of various symptoms of Alzheimer’s-related agitation and dementia, according to observational trial data published online ahead of print in The Journal of Alzheimer’s Disease.
Israeli investigators assessed the use of cannabis oil as an adjunct pharmacotherapy treatment in ten Alzheimer’s disease patients over a period of several weeks. Researchers reported that drug administration was associated with a significant reduction in patients’ symptom severity scores. Specifically, cannabis oil ingestion corresponded with decreased levels of aggression, irritability, apathy, and delusions.
Investigators concluded, “Adding medical cannabis oil to Alzheimer’s disease patients pharmacotherapy is safe and a promising treatment option.”
The administration of dronabinol (oral synthetic THC in pill form) has previously been reported to reduce Alzheimer’s-induced agitation and improve weight gain, while preclinical studies have theorized that cannabinoids may be neuroprotective against the onset of the disease.
An abstract of the study, “Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An open label, add-on, pilot study,” appears online here.
Inhaling cannabis is associated with the remission of refractory idiopathic angioedema, according to a clinical report published in the journal Case Reports in Immunology. Angioedema is a condition characterized by rapid swelling under the skin in regions around the face and throat, which may result in airway obstruction or suffocation.
Investigators from the Soroka University Medical Center in Israel reported on the progress of a 27-year-old male patient with life-threatening, recurrent angioedema of unknown origin. Doctors placed the patient on a regiment of 20 grams of inhaled cannabis monthly after he failed to respond favorably to prescribed steroids and antihistamines.
Authors reported: “The use of inhaled cannabis resulted in a complete response, and he has been free of symptoms for 2 years. An attempt to withhold the inhaled cannabis led to a recurrent attack within a week, and resuming cannabis maintained the remission, suggesting a cause and effect relationship.”
They concluded: “This is the first report in which a cannabis product for the treatment of refractory idiopathic angioedema was associated with an excellent clinical response. … More research into the exact mechanism of action of cannabis products in cases of idiopathic angioedema and on the modulation of the immune response in general is indicated.”
The Israeli government has authorized the limited production and distribution of marijuana as a medical treatment since 2011, and preparations of the plant are expected to be available in pharmacies imminently.
Full text of the report, “Life threatening idiopathic recurrent angioedema responding to cannabis,” appears online here.
Israeli investigators intend to evaluate the potential anti-tumoral effects of the canabinoid cannabidiol (CBD) in select cancer patients.
Researchers at the Hassadah Medical Center in Jerusalem will conduct a Phase II clinical trial to assess the impact of CBD as single treatment in cancer patients who have failed to respond to conventional therapies. Participants in the trial will receive CBD therapy for a period of eight weeks.
Data documenting the potent anti-cancer activity of various cannabinoids – including THC, CBD, and CBG – both in culture and in animals dates back to the mid-1970s. To date, however, virtually no clinical trials exist reproducing these results in human subjects.
In August, pharmaceutical provider Insys Therapeutics announced that it had received orphan drug status for its proprietary formulation of CBD for the treatment of glioblastoma, a hard-to-treat, aggressive form of brain cancer.
Organic CBD remains classified under federal law as a schedule I controlled substance.
Further details of the forthcoming Israeli trial are available online from the clinicaltrials.gov website here. Patient recruitment has yet to begin for this study.
The administration of a single dose of whole-plant cannabis via a thermal-metered inhaler is effective and well tolerated among patients suffering from neuropathy (nerve pain), according to clinical trial data published online ahead of print in the Journal of Pain and Palliative Care Pharmacotherapy.
Israeli investigators assessed the efficacy of a novel, portable metered-dose cannabis inhaler in eight subjects diagnosed with chronic neuropathic pain. Researchers reported that the device administered an efficient, consistent, and therapeutically effective dosage of cannabinoids to all participants.
They concluded, “This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a delta-9-THC pharmacokinetic profile with low inter-individual variation of (maximum drug/plasma concentrations), achieving pharmaceutical standards for inhaled drugs.”
A series of clinical trials conducted by investigators affiliated with the Center for Medicinal Cannabis Research at the University of California, San Diego previously determined that the inhalation of whole-plant cannabis is efficacious in the treatment of neuropathic pain.
Full text of the study, “The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: A phase 1a study,” will appear in the Journal of Pain and Palliative Care Pharmacotherapy.